Clinical
- Established dedicated Myeloma Clinic for new referrals of patients with plasma cell dyscrasias including multiple myeloma, smouldering myeloma, MGUS and AL amyloidosis.
Clinical Trials and Registry
- Entered and maintain up to date data for all St Vincent’s patients diagnosed with myeloma from November 2017 onwards in the Australian and New Zealand Myeloma and Related Diseases Registry. Contributed additional data for IMPROVE study examining intravenous immunoglobulin use.
- Selected as a site for ALL-G trials FRAIL-M (frailty stratified therapy for newly diagnosed MM), IRIL (isatuxumab rescue for patients with inadequate response to lenalidomide/dexamethasone) and SeaLAND (addition of selinexor to lenalidomide in maintenance)
- Selected as a site for DREAMM8: belantamab-pomalidomide-dexamethasone versus pomalidomide-bortezomib-dexamethasone.
- Selected as a site for BelaCarD, an AMARC study evaluating belantamab mafodotin and carfilzomib in Relapsed/Refractory multiple myeloma
- Pursued and signed CDA with Celgene/BMS
- At feasibility stage with other pharmaceutical companies regarding immunotherapy trials (confidential discussions)
